Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration

NCT06660667 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06660667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 21, 2024
Completion date
June 30, 2031
Enrollment
66 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration